Pfizer (PFE) grabbed investors’ attention after signing a pricing agreement with the Trump administration. Meanwhile, analysts have responded positively, reaffirming their Buy ratings on PFE stock. On ...

The general mood among these heavyweight investors is divided, with 44% leaning bullish and 55% bearish. Among these notable options, 6 are puts, totaling $448,868, and 3 are calls, amounting to ...

Pfizer’s PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January. Image Source: Zacks ...

Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion. PFE is ...

Pfizer is deeply undervalued, trading at a multi-year low with a 6.65% dividend yield, making it a compelling long-term opportunity. Recent double-digit earnings growth, strong margins, and cost ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

I last covered Pfizer Inc. (PFE) stock on 8/6 with an article titled “Pfizer Q2: Dividends Speak Louder Than EPS”. The article was triggered by the company’s earnings report (ER) for Q2 2025 and rated ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated a Buy rating on Pfizer Inc. (NYSE:PFE) on December 17 and set a price ...